BioCentury | Apr 30, 2012
Emerging Company Profile

Ariel: Antagonizing pain

...rates of non-responders, the pipeline for acute pain continues to be short on novel targets. Ariel Pharmaceuticals Inc....
...first tranche of a $15 million series A round this year. Companies and Institutions Mentioned Ariel Pharmaceuticals Inc....
...York N.Y. RaQualia Pharma Inc. (JASDAQ:4579), Aichi, Japan University of Minnesota , Minneapolis, Minn. Sidebars Ariel Pharmaceuticals Inc....
BioCentury | Sep 26, 2011
Company News

Ariel Pharmaceuticals, BTG deal

...received a chemical library of PTGER4 antagonist ligands and screening tools. Details were not disclosed. Ariel Pharmaceuticals Inc....
Items per page:
1 - 2 of 2
BioCentury | Apr 30, 2012
Emerging Company Profile

Ariel: Antagonizing pain

...rates of non-responders, the pipeline for acute pain continues to be short on novel targets. Ariel Pharmaceuticals Inc....
...first tranche of a $15 million series A round this year. Companies and Institutions Mentioned Ariel Pharmaceuticals Inc....
...York N.Y. RaQualia Pharma Inc. (JASDAQ:4579), Aichi, Japan University of Minnesota , Minneapolis, Minn. Sidebars Ariel Pharmaceuticals Inc....
BioCentury | Sep 26, 2011
Company News

Ariel Pharmaceuticals, BTG deal

...received a chemical library of PTGER4 antagonist ligands and screening tools. Details were not disclosed. Ariel Pharmaceuticals Inc....
Items per page:
1 - 2 of 2